Lung cancer patients treated with the blockbuster drug Osimertinib (Tagrisso) eventually develop resistance. We identified a novel MERTK-dependent escape mechanism, that occurs even in the absence of new mutations and is estimated to account for more than 60% of resistance cases. ... Read more

We disclose a novel approach to bypass dose-limiting toxicity of 4-1BB agonists, the major limiting factor for the clinical development of 4-1BB mAbs for cancer immunotherapy: mutating 4-1BB ligand to attenuate its potency and fusing it to an antibody targeting defined immune cells which contribu ... Read more

Inflammatory bowel disease (IBD) remains a major unmet medical need, with current therapies relying on chronic immunosuppression rather than restoring immune tolerance. ... Read more